JP2004532867A - 性快感消失症の治療用薬物の調製のためのアルカノイルｌ−カルニチンの使用 - Google Patents

性快感消失症の治療用薬物の調製のためのアルカノイルｌ−カルニチンの使用 Download PDF

Info

Publication number
JP2004532867A
JP2004532867A JP2002592921A JP2002592921A JP2004532867A JP 2004532867 A JP2004532867 A JP 2004532867A JP 2002592921 A JP2002592921 A JP 2002592921A JP 2002592921 A JP2002592921 A JP 2002592921A JP 2004532867 A JP2004532867 A JP 2004532867A
Authority
JP
Japan
Prior art keywords
carnitine
stress
acetyl
rats
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002592921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532867A5 (enExample
Inventor
メノッティ・カルヴァーニ
ルイジ・モスコーニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT2001RM000292A external-priority patent/ITRM20010292A1/it
Priority claimed from IT2001RM000319A external-priority patent/ITRM20010319A1/it
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2004532867A publication Critical patent/JP2004532867A/ja
Publication of JP2004532867A5 publication Critical patent/JP2004532867A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002592921A 2001-05-29 2002-05-24 性快感消失症の治療用薬物の調製のためのアルカノイルｌ−カルニチンの使用 Pending JP2004532867A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2001RM000292A ITRM20010292A1 (it) 2001-05-29 2001-05-29 Uso dell'acetil l-carnitina per la preparazione di un medicamento peril trattamento dell'anedonia.
IT2001RM000319A ITRM20010319A1 (it) 2001-06-08 2001-06-08 Uso di una alcanoil l-carnitina per la preparazione di un medicamentoper il trattamento dell'anedonia.
PCT/IT2002/000339 WO2002096411A1 (en) 2001-05-29 2002-05-24 Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia

Publications (2)

Publication Number Publication Date
JP2004532867A true JP2004532867A (ja) 2004-10-28
JP2004532867A5 JP2004532867A5 (enExample) 2006-01-05

Family

ID=26332845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002592921A Pending JP2004532867A (ja) 2001-05-29 2002-05-24 性快感消失症の治療用薬物の調製のためのアルカノイルｌ−カルニチンの使用

Country Status (16)

Country Link
US (2) US20040171685A1 (enExample)
EP (1) EP1399143B1 (enExample)
JP (1) JP2004532867A (enExample)
KR (1) KR20040003031A (enExample)
AT (1) ATE345124T1 (enExample)
CA (1) CA2448246A1 (enExample)
CZ (1) CZ20033222A3 (enExample)
DE (1) DE60216090T2 (enExample)
DK (1) DK1399143T3 (enExample)
ES (1) ES2275881T3 (enExample)
HU (1) HUP0400007A2 (enExample)
MX (1) MXPA03010920A (enExample)
PL (1) PL367628A1 (enExample)
PT (1) PT1399143E (enExample)
SK (1) SK15862003A3 (enExample)
WO (1) WO2002096411A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
CA3238205A1 (en) 2021-11-12 2023-05-19 Rajaram Samant A synergistic composition for activating intracellular secondary messenger(camp) pathway

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1291930B1 (it) * 1997-06-18 1999-01-21 Sigma Tau Ind Farmaceuti Composizione riequilibratrice delle turbe dell'umore in individui sani

Also Published As

Publication number Publication date
DE60216090T2 (de) 2007-05-31
CZ20033222A3 (cs) 2004-06-16
DE60216090D1 (de) 2006-12-28
WO2002096411A1 (en) 2002-12-05
SK15862003A3 (sk) 2004-06-08
KR20040003031A (ko) 2004-01-07
US20040171685A1 (en) 2004-09-02
ES2275881T3 (es) 2007-06-16
HUP0400007A2 (hu) 2004-04-28
CA2448246A1 (en) 2002-12-05
PL367628A1 (en) 2005-03-07
PT1399143E (pt) 2007-01-31
EP1399143A1 (en) 2004-03-24
EP1399143B1 (en) 2006-11-15
ATE345124T1 (de) 2006-12-15
US20060148896A1 (en) 2006-07-06
DK1399143T3 (da) 2007-03-26
MXPA03010920A (es) 2004-02-27

Similar Documents

Publication Publication Date Title
US6335361B1 (en) Method of treating benign forgetfulness
Bonkowsky et al. Neurologic manifestations of acute porphyria
CA3148256A1 (en) Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
EP3342409A1 (en) Anti-fatigue agent
JPH0643299B2 (ja) 薬剤療法
DE60220899T2 (de) Mittel gegen stressinduzierte krankheiten
DE60011650T2 (de) Synergistische kombination von nk1-rezeptor antagonisten und gaba analogen
JP2004532867A (ja) 性快感消失症の治療用薬物の調製のためのアルカノイルｌ−カルニチンの使用
Bergeron et al. Regional alterations of dopamine and its metabolites in rat brain following portacaval anastomosis
KR102722498B1 (ko) 인지 기능 개선용 조성물 및 불안양 증상 개선용 조성물, 및 뇌 위축 억제용 조성물
DE3527356A1 (de) Verfahren zur verbesserung der fruchtbarkeit von haustieren
US20200054665A1 (en) Compositions and methods that attenuate cognitive aging in individuals who do not have dementia
Boyce et al. Onset and Progression of Motor Deficits in Motor Neuron Degeneration (mnd) Mice Are Unaltered by the Glycine/NMDA Receptor Antagonist L-701,324 or the MAO-B Inhibitorr (−)-Deprenyl
Jucker et al. Effects of brovincamine on stereological capillary parameters in adult and old Fischer-344 rats
EP2044944A1 (en) Nootropic medicinal agent
CA2585560C (en) Use of acetyl l-carnitine for the treatment of fibromyalgic syndrome
Şahin et al. Impairment of motor coordination in mice after ingestion of aluminum chloride
KR20070042963A (ko) 당뇨병 환자의 신경병 통증 치료용 약제의 제조를 위한아세틸 엘 카르니틴의 용도
EP0344158A1 (de) Schmerzpräparat.
Samour et al. Use of ammonium chloride in falconry in the Middle East
WO2018189022A1 (en) Compositions and methods that attenuate cognitive aging in individuals who do not have dementia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090414